Online inquiry

IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7136MR)

This product GTTS-WQ7136MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LHCGR gene. The antibody can be applied in Controlled Ovarian Stimulation (COS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000233.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3973
UniProt ID P22888
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ7136MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15295MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ623MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ5313MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ6706MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ3090MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ6576MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ6478MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ5258MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CB-6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW